Stability of carboplatin in 5% glucose solution exposed to light

Torres, Frank E.; Girona, Victòria; Puiol, M.; Prat, Josefina; Bolós, J.

doi:10.1016/0378-5173(95)04138-9

Cited by 6 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the stability of these new platinum compounds in solution was explored, since many differences in the action of cisplatin and second-generation compounds have been found, depending on the test conditions, such as light and solvent. [17][18][19][20][21][22][23][24][25][26][27] The present contribution describes the synthesis, crystal structure, and solution behavior of these two new fluorescent platinum(II) compounds in DMSO. In addition, the cytotoxic activity of both platinum(II) compounds and their corresponding carrier ligands was measured in human tumor cell lines, including human ovarian carcinoma cell line A2780 and its cisplatin-resistant counterpart A2780R.…”

Section: Introductionmentioning

confidence: 99%

“…Because the carrier ligand A9opy is coordinated to the platinum(II) ion through the isomerizable carbon−carbon double bond in compound 1 , the study of such a compound in solution, and the influence of the light in its stability toward isomerization of the coordinated carbon−carbon double bond, was undertaken and performed by NMR spectroscopy. In addition, the stability of these new platinum compounds in solution was explored, since many differences in the action of cisplatin and second-generation compounds have been found, depending on the test conditions, such as light and solvent. − The present contribution describes the synthesis, crystal structure, and solution behavior of these two new fluorescent platinum(II) compounds in DMSO. In addition, the cytotoxic activity of both platinum(II) compounds and their corresponding carrier ligands was measured in human tumor cell lines, including human ovarian carcinoma cell line A2780 and its cisplatin-resistant counterpart A2780R.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Synthesis, Crystal Structure, Studies in Solution and Cytotoxicity of Two New Fluorescent Platinum(II) Compounds Containing Anthracene Derivatives as a Carrier Ligand

et al. 2008

View full text Add to dashboard Cite

Two new cytotoxic fluorescent platinum(II) compounds, cis-[Pt(A9opy)Cl2] (1) and cis-[Pt(A9pyp)(DMSO)Cl2] (2),have been designed, synthesized, and characterized by IR, 1H NMR, and 195Pt NMR spectroscopy; electrospray ionization mass spectrometry (ESI-MS); and single-crystal X-ray diffraction. The carrier ligands selected for thesynthesis of these fluorescent platinum(II) compounds are E-2-[1-(9-anthryl)-3-oxo-3-prop-2-enylpyridine] (abbreviatedas A9opy) and E-1-(9-anthryl)-3-(2-pyridyl)-2-propenone (abbreviated as A9pyp). The compound cis-[Pt(A9opy)Cl2](1) comprises a peculiar cis-platinum(II) organometallic compound, in which the platinum(II) ion is bound to the photoisomerizable carbon-carbon double bond of the carrier ligand. The effects of the metal-ion coordination on the photoisomerization of the carbon-carbon double bond of the ligand have been studied. In contrast, the carrier ligand A9pyp used for the synthesis of the cis-[Pt(A9pyp)(DMSO)Cl2] compound (2) does not undergo such anisomerization process and remains in the E conformation, while coordinated to the platinum(II) ion through the nitrogen of the pyridine ring. In addition to the synthesis and characterization, solution studies of both compounds have also been performed in detail, including NMR and ESI-MS spectroscopy. Moreover, a high degree of cytotoxicactivity of compound 1 was found, as compared to cisplatin and its corresponding platinum-free molecule, in a series of human tumor cell lines. Compound 2 was also found to be highly active against these cell lines but appeared less active compared to the platinum-free molecule.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Synthesis, Crystal Structure, Studies in Solution and Cytotoxicity of Two New Fluorescent Platinum(II) Compounds Containing Anthracene Derivatives as a Carrier Ligand

et al. 2008

View full text Add to dashboard Cite

show abstract

“…14,22,37,38 For instance, Torres et al 22 found that in 0.8 mg/mL and 3.2 mg/mL solutions of carboplatin-5% glucose exposed to light, 10% degradation occurred within 1-10 h depending on light intensity. 22 Similarly, Pujol et al 38 found that carboplatin Table 1. Chemical stability of carboplatin 0.5 mg/mL, 2.0 mg/mL, and 4.0 mg/mL solutions prepared in 0.9% sodium chloride in PVC bags.…”

Section: Discussionmentioning

confidence: 99%

“…11,12 Accordingly, the final diluted infusion solutions are stable up to 8 h at 25 C. 11,12 Currently, there is an abundance of stability data on carboplatin solutions prepared in D5W. [13][14][15][16][17][18][19][20][21][22] Many of these studies have been reviewed elsewhere, 23 and a comprehensive review of the data is beyond the scope of this manuscript. In brief, the stability of carboplatin-D5W infusion solutions stored at room temperature ($25 C) ranges from 1 day to 30 days in various administration packages.…”

Section: Introductionmentioning

confidence: 99%

Stability study of carboplatin infusion solutions in 0.9% sodium chloride in polyvinyl chloride bags

Myers

Zhang

Kawedia

et al. 2014

J Oncol Pharm Pract

View full text Add to dashboard Cite

The extended physico-chemical stability of carboplatin prepared in sodium chloride reported herein permits advance preparation of these admixtures, facilitating pharmacy utility and operations. Since no antibacterial preservative is contained within these carboplatin solutions, we recommend storage, when prepared under specified aseptic conditions, no greater than 24 h at room temperature or three days under refrigeration.

show abstract

“…However, illuminance under ordinary ‰uorescent lamps is about 0.2 1.0 kLux, diŠer-ing considerably from outdoor illuminance (under a roof) value of 48.82±6.01 kLux used in the present study. Torres et al 3) showed that stabilities was dened as ＜10％ loss of initial drug concentration when the samples were exposed under diŠerent illumination conditions. Carballar et al 4) demonstrated a degradation of ＞50％ of initial condition under 105, 143, and ＞200 kLx with a 250 W Xe lamp.…”

Section: Discussionmentioning

confidence: 99%

Light-induced Deterioration Test of Carboplatin under Clinical Settings

et al. 2010

View full text Add to dashboard Cite

Chemotherapeutic drug dosages are calculated precisely based on the patient's height, body weight, and renal function, etc. To ensure safe and favorable outcomes of treatment, dosing solutions are prepared by appropriate mixing of the drug solutions based on such calculations. The package inserts for many injectable preparations include a warning for storing the product``shielded from light.'' However, there are no reports of stability assessment of a mixed product against light exposure or the residual amount of active ingredient in the dosing solution during or at the end of treatment. We evaluated the stability of carboplatin from the time of mixing of the dosing solution until the end of drug infusion in a clinical-like setting. With 4-hour exposure to outdoor scattered light, the dosing solution began to show discoloration by 1 hour, becoming dark yellow by 4 hours, with reduction of the percent residual carboplatin to about 23％. To identify the optimal light-shielding shade, the dosing solution was shielded from outdoor scattered light with 1 of 3 protective covers: aluminum foil, yellow plastic shade, and brown plastic shade. The yellow plastic shade prevented any changes of the appearance of the dosing solution during the 4-hour exposure period. The percent residual carboplatin, determined by HPLC, in the dosing solution shielded with a yellow plastic shade was about 85.2％ at 2 hours and 78.6％ at 4 hours. Thus carboplatin dosing solution should be completely shielded from light until infusion is completed.

show abstract

Stability of carboplatin in 5% glucose solution exposed to light

Cited by 6 publications

References 4 publications

Synthesis, Crystal Structure, Studies in Solution and Cytotoxicity of Two New Fluorescent Platinum(II) Compounds Containing Anthracene Derivatives as a Carrier Ligand

Synthesis, Crystal Structure, Studies in Solution and Cytotoxicity of Two New Fluorescent Platinum(II) Compounds Containing Anthracene Derivatives as a Carrier Ligand

Stability study of carboplatin infusion solutions in 0.9% sodium chloride in polyvinyl chloride bags

Light-induced Deterioration Test of Carboplatin under Clinical Settings

Contact Info

Product

Resources

About